| Sep 9 |
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
|
| Sep 9 |
Relay stock rallies 41% on positive data for RLY-2608
|
| Sep 9 |
Relay breast cancer drug shows potential in early trial
|
| Sep 9 |
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
|
| Sep 6 |
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
|
| Aug 7 |
Expert Ratings For Relay Therapeutics
|
| Aug 6 |
Relay Therapeutics GAAP EPS of -$0.69 beats by $0.04
|
| Aug 6 |
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
|
| Jul 30 |
Relay Therapeutics to Announce Second Quarter 2024 Financial Results and Corporate Highlights on August 6, 2024
|
| Jul 24 |
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
|
